US-based biotechnology company NeuroKaire said on Thursday that it has entered a research and development collaboration with UK-based pharmaceutical company Compass Pathways (NASDAQ: CMPS), which focusses on transforming mental health care through psychedelic therapies.

The partnership will investigate how psychedelic compounds influence brain cell structure and connectivity using patient-derived neurons from individuals with treatment-resistant depression and major depressive disorder.

NeuroKaire's proprietary platform combines advanced biology with AI-powered image analysis to study how compounds affect communication between neurons through a unique neuroplasticity marker. This approach aims to provide cellular-level insight into how potential treatments work and differ.

NeuroKaire says this collaboration reflects a growing shift in psychiatry towards integrating human biology and machine learning to bridge the gap between preclinical research and real-world patient outcomes.